Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and alzheimer dementia in blacks and whites: A report from the Einstein aging study

Mindy Joy Katz, Richard B. Lipton, Charles B. Hall, Molly E. Zimmerman, Amy E. Sanders, Joe Verghese, Dennis W. Dickson, Carol A. Derby

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

As the population ages, the need to characterize rates of cognitive impairment and dementia within demographic groups defined by age, sex, and race becomes increasingly important. There are limited data available on the prevalence and incidence of amnestic mild cognitive impairment (aMCI) and nonamnestic mild cognitive impairment (naMCI) from population-based studies. The Einstein Aging Study, a systematically recruited community-based cohort of 1944 adults aged 70 or older (1168 dementia free at baseline; mean age, 78.8 y; average follow-up, 3.9 y), provides the opportunity to examine the prevalence and incidence rates for dementia, Alzheimer dementia (AD), aMCI, and naMCI by demographic characteristics. Dementia prevalence was 6.5% (4.9% AD). Overall dementia incidence was 2.9/100 person-years (2.3/100 person-years for AD). Dementia and AD rates increased with age but did not differ by sex. Prevalence of aMCI was 11.6%, and naMCI prevalence was 9.9%. aMCI incidence was 3.8 and naMCI incidence was 3.9/100 person-years. Rates of aMCI increased significantly with age in men and in blacks; sex, education, and race were not significant risk factors. In contrast, naMCI incidence did not increase with age; however, blacks were at higher risk compared with whites, even when controlling for sex and education. Results highlight the public health significance of preclinical cognitive disease.

Original languageEnglish (US)
Pages (from-to)335-343
Number of pages9
JournalAlzheimer Disease and Associated Disorders
Volume26
Issue number4
DOIs
StatePublished - Oct 2012

Fingerprint

Dementia
Alzheimer Disease
Incidence
Sex Education
Cognitive Dysfunction
hydroquinone
Demography
Population
Public Health
Age Groups

Keywords

  • Alzheimer dementia
  • amnestic mild cognitive impairment
  • cohort study
  • dementia
  • nonamnestic mild cognitive impairment

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Gerontology
  • Clinical Psychology

Cite this

@article{1d3e416a8a354dbd8976ffc19d95b0ee,
title = "Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and alzheimer dementia in blacks and whites: A report from the Einstein aging study",
abstract = "As the population ages, the need to characterize rates of cognitive impairment and dementia within demographic groups defined by age, sex, and race becomes increasingly important. There are limited data available on the prevalence and incidence of amnestic mild cognitive impairment (aMCI) and nonamnestic mild cognitive impairment (naMCI) from population-based studies. The Einstein Aging Study, a systematically recruited community-based cohort of 1944 adults aged 70 or older (1168 dementia free at baseline; mean age, 78.8 y; average follow-up, 3.9 y), provides the opportunity to examine the prevalence and incidence rates for dementia, Alzheimer dementia (AD), aMCI, and naMCI by demographic characteristics. Dementia prevalence was 6.5{\%} (4.9{\%} AD). Overall dementia incidence was 2.9/100 person-years (2.3/100 person-years for AD). Dementia and AD rates increased with age but did not differ by sex. Prevalence of aMCI was 11.6{\%}, and naMCI prevalence was 9.9{\%}. aMCI incidence was 3.8 and naMCI incidence was 3.9/100 person-years. Rates of aMCI increased significantly with age in men and in blacks; sex, education, and race were not significant risk factors. In contrast, naMCI incidence did not increase with age; however, blacks were at higher risk compared with whites, even when controlling for sex and education. Results highlight the public health significance of preclinical cognitive disease.",
keywords = "Alzheimer dementia, amnestic mild cognitive impairment, cohort study, dementia, nonamnestic mild cognitive impairment",
author = "Katz, {Mindy Joy} and Lipton, {Richard B.} and Hall, {Charles B.} and Zimmerman, {Molly E.} and Sanders, {Amy E.} and Joe Verghese and Dickson, {Dennis W.} and Derby, {Carol A.}",
year = "2012",
month = "10",
doi = "10.1097/WAD.0b013e31823dbcfc",
language = "English (US)",
volume = "26",
pages = "335--343",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and alzheimer dementia in blacks and whites

T2 - A report from the Einstein aging study

AU - Katz, Mindy Joy

AU - Lipton, Richard B.

AU - Hall, Charles B.

AU - Zimmerman, Molly E.

AU - Sanders, Amy E.

AU - Verghese, Joe

AU - Dickson, Dennis W.

AU - Derby, Carol A.

PY - 2012/10

Y1 - 2012/10

N2 - As the population ages, the need to characterize rates of cognitive impairment and dementia within demographic groups defined by age, sex, and race becomes increasingly important. There are limited data available on the prevalence and incidence of amnestic mild cognitive impairment (aMCI) and nonamnestic mild cognitive impairment (naMCI) from population-based studies. The Einstein Aging Study, a systematically recruited community-based cohort of 1944 adults aged 70 or older (1168 dementia free at baseline; mean age, 78.8 y; average follow-up, 3.9 y), provides the opportunity to examine the prevalence and incidence rates for dementia, Alzheimer dementia (AD), aMCI, and naMCI by demographic characteristics. Dementia prevalence was 6.5% (4.9% AD). Overall dementia incidence was 2.9/100 person-years (2.3/100 person-years for AD). Dementia and AD rates increased with age but did not differ by sex. Prevalence of aMCI was 11.6%, and naMCI prevalence was 9.9%. aMCI incidence was 3.8 and naMCI incidence was 3.9/100 person-years. Rates of aMCI increased significantly with age in men and in blacks; sex, education, and race were not significant risk factors. In contrast, naMCI incidence did not increase with age; however, blacks were at higher risk compared with whites, even when controlling for sex and education. Results highlight the public health significance of preclinical cognitive disease.

AB - As the population ages, the need to characterize rates of cognitive impairment and dementia within demographic groups defined by age, sex, and race becomes increasingly important. There are limited data available on the prevalence and incidence of amnestic mild cognitive impairment (aMCI) and nonamnestic mild cognitive impairment (naMCI) from population-based studies. The Einstein Aging Study, a systematically recruited community-based cohort of 1944 adults aged 70 or older (1168 dementia free at baseline; mean age, 78.8 y; average follow-up, 3.9 y), provides the opportunity to examine the prevalence and incidence rates for dementia, Alzheimer dementia (AD), aMCI, and naMCI by demographic characteristics. Dementia prevalence was 6.5% (4.9% AD). Overall dementia incidence was 2.9/100 person-years (2.3/100 person-years for AD). Dementia and AD rates increased with age but did not differ by sex. Prevalence of aMCI was 11.6%, and naMCI prevalence was 9.9%. aMCI incidence was 3.8 and naMCI incidence was 3.9/100 person-years. Rates of aMCI increased significantly with age in men and in blacks; sex, education, and race were not significant risk factors. In contrast, naMCI incidence did not increase with age; however, blacks were at higher risk compared with whites, even when controlling for sex and education. Results highlight the public health significance of preclinical cognitive disease.

KW - Alzheimer dementia

KW - amnestic mild cognitive impairment

KW - cohort study

KW - dementia

KW - nonamnestic mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84870247069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870247069&partnerID=8YFLogxK

U2 - 10.1097/WAD.0b013e31823dbcfc

DO - 10.1097/WAD.0b013e31823dbcfc

M3 - Article

C2 - 22156756

AN - SCOPUS:84870247069

VL - 26

SP - 335

EP - 343

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 4

ER -